Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm by Site — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site

Other

Neoplasm by Site

CI-CAN-00000003Explore in graph →

Non-malignant20,504 active trials253 approved drugs3,568 evidence items

NCIt: C3263
MeSH: D009371

Overview
Statistics
Survival
Genomics537
Variants & evidence3568
Drugs398
Trials92622
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,460)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,651–3,675 of 4,460 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
· J Thorac Oncol · 2013 · PMID 23524406 · validated civic_curation pubmed
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
· Leukemia · 2014 · PMID 25212276 · validated civic_curation pubmed
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
· J Thorac Oncol · 2013 · PMID 23584301 · validated civic_curation pubmed
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed
Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
· Oncotarget · 2015 · PMID 26423602 · validated civic_curation pubmed
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.
· Nat Med · 2014 · PMID 24836576 · validated civic_curation pubmed
Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
· J Thorac Oncol · 2016 · PMID 26724472

Showing 3,651–3,675 of 4,460 publications

← Previous
1
…
146
147
148
…
179
Next →

· validated civic_curation

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

· Lung Cancer · 2014 · PMID 24192513 · validated civic_curation pubmed

A practical approach to aid physician interpretation of clinically actionable predictive biomarker results in a multi-platform tumor profiling service.

· Front Pharmacol · 2014 · PMID 24782778 · validated civic_curation pubmed

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

· J Clin Oncol · 2011 · PMID 22025163 · validated civic_curation pubmed

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

· Clin Cancer Res · 2013 · PMID 23434733 · validated civic_curation pubmed

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

· Cancer Chemother Pharmacol · 2009 · PMID 18607592 · validated civic_curation pubmed

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

· Gynecol Oncol · 2006 · PMID 16487996 · validated civic_curation pubmed

A novel fusion gene, SYT-SSX4, in synovial sarcoma.

· J Natl Cancer Inst · 1999 · PMID 10359553 · validated civic_curation pubmed

Breast cancer in a RAD51D mutation carrier: case report and review of the literature.

· Clin Breast Cancer · 2015 · PMID 25445424 · validated civic_curation pubmed

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

· BMC Cancer · 2012 · PMID 23181703 · validated civic_curation pubmed

A novel K-ras mutation in colorectal cancer. A case report and literature review.

· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

· J Clin Oncol · 2010 · PMID 20940188 · validated civic_curation pubmed

Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

· Eur J Haematol · 2014 · PMID 24330038 · validated civic_curation pubmed

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

· Jpn J Clin Oncol · 2010 · PMID 20522446 · validated civic_curation pubmed

Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.

· Oncotarget · 2014 · PMID 25015329 · validated civic_curation pubmed

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

· Cancer Discov · 2015 · PMID 26370156 · validated civic_curation pubmed

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

· J Clin Oncol · 2008 · PMID 18390968 · validated civic_curation pubmed

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

· J Thorac Oncol · 2014 · PMID 25393796 · validated civic_curation pubmed

Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion.

· Mol Genet Genomic Med · 2015 · PMID 25802883 · validated civic_curation pubmed